Psychiatr. praxi. 2013;14(1):22-25

Escitalopram: new clinical findings

prof.MUDr.Jiří Horáček, Ph.D.
Psychiatrické centrum Praha, 3. lékařská fakulta Univerzity Karlovy Praha, Národní ústav duševního zdraví

This short overview is aimed at new clinical findings in escitalopram treatment. Studies published within a period of past two years were

focused at pooled analyses comparing escitalopram with new antidepressants (agomelatine and SNRI), efficacy and safety in older and

somatically ill patients (breast cancer, asthma bronchiale, acute coronary syndrome, vasomotor symptoms in menopause). The positive

effect of escitalopram on gray matter volume has been documented in patients with panic disorder. Escitalopram treatment can be

eased by the new form of orodispersible tablets.

symptoms in menopause.

Keywords: escitalopram, agomelatine, SNRI, antidepressants, breast cancer, asthma bronchiale, acute coronary syndrome, vasomotor

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horáček J. Escitalopram: new clinical findings. Psychiatr. praxi. 2013;14(1):22-25.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174: 163-176. Go to original source... Go to PubMed...
    2. Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006b; 21: 105-110. Go to original source... Go to PubMed...
    3. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002; 7: 40-44. Go to original source... Go to PubMed...
    4. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149-155. Go to original source... Go to PubMed...
    5. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59: 268-275. Go to original source... Go to PubMed...
    6. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758. Go to original source... Go to PubMed...
    7. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 2009; 14: 326-333. Go to original source... Go to PubMed...
    8. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH: Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin 2011; 27: 1089-1096. Go to original source... Go to PubMed...
    9. Quera-Salva MA, Hajak G, Philip P, Montplaisir J, KeuferLe GS, Laredo J, Guilleminault C. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol 2011; 26: 252-262. Go to original source... Go to PubMed...
    10. Lai CH, Wu YT. Changes in gray matter volume of remitted first-episode, drug-naive, panic disorder patients after 6-week antidepressant therapy. J Psychiatr Res 2013; 47: 122-127. Go to original source... Go to PubMed...
    11. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012; 52: 6-17. Go to original source... Go to PubMed...
    12. Tsui JI, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. Pain 2011; 152: 2640-2644. Go to original source... Go to PubMed...
    13. Hansen BH, Hanash JA, Rasmussen A, Hansen JF, Andersen NL, Nielsen OW, Birket-Smith M. Effects of escitalopram in prevention of depression in patients with acute coronary syndrome (DECARD). J Psychosom Res 2012; 72: 11-16. Go to original source... Go to PubMed...
    14. Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics 2012; 53: 75-80. Go to original source... Go to PubMed...
    15. Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, openlabel prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 2012; 36: 318-323. Go to original source... Go to PubMed...
    16. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol 2012. Go to original source... Go to PubMed...
    17. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17: 343-362. Go to original source... Go to PubMed...
    18. Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15: 581-593. Go to original source... Go to PubMed...
    19. Horacek J. Účinnost a bezpečnost escitalopramu u osob ve vyšším věku: spojená (poolovaná) analýza pěti otevřených sledování. Psychiatrie pro praxi 2011; 12: 22-26.
    20. Kasper S, de SH, Friis AH. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13: 884-891. Go to original source...
    21. Kasper S, Lemming OM, de SH. Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology 2006a; 54: 152-159. Go to original source... Go to PubMed...
    22. Lyketsos CG, Weiller E, Katona C, Gorwood P. Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? BMC Geriatr 2011; 11: 2. Go to original source... Go to PubMed...
    23. Lacroix AZ, Freeman EW, Larson J, Carpenter JS, Joffe H, Reed SD, Newton KM, Seguin RA, Sternfeld B, Cohen L, Ensrud KE. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. Maturitas 2012; 73: 361-368. Go to original source... Go to PubMed...
    24. Joffe H, Guthrie KA, Larson J, Cohen LS, Carpenter JS, Lacroix AZ, Freeman EW. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the Menopause Strategies: Finding Lasting Answers for Symptoms and Health Research Network. Menopause 2012. Go to original source...
    25. Nilausen DO, Zuiker RG, van GJ. The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Clin Ther 2011; 33: 1492-1502. Go to original source... Go to PubMed...
    26. Wade AG, Crawford GM, Young D. A survey of patient preferences for a placebo orodispersible tablet. Patient Prefer Adherence 2012; 6: 201-206. Go to original source... Go to PubMed...
    27. Navarro V. Improving medication compliance in patients with depression: Use of orodispersible tablets. Adv Ther 2010; 27: 785-795. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.